Puma Biotechnology EV/EBIT PBYI
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.
- Today, Nov 2, 2026
- 14.2×
- 5-year median
- 6.3×
- Against its 5-year history
- 87th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 2.8× to 112×
- Peer median
- 4.7×
Puma Biotechnology's EV/EBIT is 14.2× as of Nov 2, 2026.
That is above its 5-year median of 6.3×, higher than on 87% of days in the last 5 years.
Over that time it ranged from 2.8× in Mar 2023 to 112× in Jun 2021.
The median for 10 large drugmakers of a similar size is 4.7×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 14.2× | 5.8× | 15.6× |
| 2025 | 7.4× | 2.9× | 7.4× |
| 2024 | 4.1× | 3.1× | 9.2× |
| 2023 | 5.4× | 2.8× | 8.7× |
| 2022 | 7.7× | 5.2× | 43.9× |
| 2021 | 73.5× | 73.5× | 112× |
Against its peers
Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| PBYIPuma Biotechnology | 14.2× |
| ARVNArvinas | n/m |
| IRWDIronwood Pharmaceuticals | 3.5× |
| ZVRAZevra Therapeutics | 3.0× |
| CRMDCorMedix | 1.4× |
| COLLCollegium Pharmaceutical | 9.5× |
| ABUSArbutus Biopharma | 4.7× |
| AMPHAmphastar Pharmaceuticals | 12.9× |
| OMEROmeros | n/m |
| NATRNatures Sunshine Products | 5.1× |
| ANABAnaptysbio | n/m |
| Peer median | 4.7× |
Where Puma Biotechnology ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Puma Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.